hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06293963, orgStudyIdInfo id: 24-0300a, briefTitle: Front-of-package Label Effects in Latine and Limited English Proficiency Populations, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-29, primaryCompletionDateStruct date: 2024-04-15, completionDateStruct date: 2024-04-15, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: University of North Carolina, Chapel Hill, class: OTHER, collaborators name: Duke University, collaborators name: Stanford University, descriptionModule briefSummary: The goal of this experiment is to examine the effects of 4 types of front-of-package food labels among a sample of Latino adults. The main questions this experiment aims to answer are:What front-of-package label design is most effective in helping Latino and low English proficiency consumers identify healthier and less healthy food products?What front-of-package label design is most effective in helping Latino and low English proficiency consumers choose healthier food products?Additionally, this experiment also aims to answer the following question:Do the benefits of front-of-package label designs differ by English proficiency and parental status?Participants will be randomly assigned to 1 of 4 types of front-of-package label designs and view their assigned label design on 3 sets of products. Each set will display 3 similar products, each high in either 1, 2, or 3 nutrients of concern. For each set, participants will select the product that they believe to be the healthiest, least healthy, and the product that they would most want to consume. Researchers will compare results across label designs., conditionsModule conditions: Diet, Healthy, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 4000, type: ESTIMATED, armsInterventionsModule interventions name: Guideline Daily Amounts label, interventions name: Interpretive text-only label, interventions name: Interpretive magnifying glass icon label, interventions name: Separated interpretive magnifying glass icon label, outcomesModule primaryOutcomes measure: Selection of healthiest product for purchase, secondaryOutcomes measure: Correct identification of healthiest product, secondaryOutcomes measure: Correct identification of least healthy product, secondaryOutcomes measure: Correct identification of products high in nutrients, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 55 Years, stdAges: ADULT, contactsLocationsModule locations facility: The University of North Carolina at Chapel Hill's Gillings School of Global Public Health, city: Chapel Hill, state: North Carolina, zip: 27599, country: United States, contacts name: Marissa G Hall, PhD, role: CONTACT, phone: 919-445-1310, email: mghall@unc.edu, geoPoint lat: 35.9132, lon: -79.05584, hasResults: False
protocolSection identificationModule nctId: NCT06293950, orgStudyIdInfo id: AUTISM, briefTitle: Allogeneic Wharton Jelly Mesenchymal Stromal Cell (WJMSC) for Treatment of Autism, statusModule overallStatus: RECRUITING, startDateStruct date: 2022-03-09, primaryCompletionDateStruct date: 2024-06, completionDateStruct date: 2024-12, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: University of Jordan, class: OTHER, descriptionModule briefSummary: Autism spectrum disorders (ASDs) are characterized by core domains: persistent deficits in social communication and interaction; restricted, repetitive patterns of behavior, interests, or activities., conditionsModule conditions: Autism, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 14, type: ESTIMATED, armsInterventionsModule interventions name: WJMSC, outcomesModule primaryOutcomes measure: safety profile lab tests, secondaryOutcomes measure: efficacy change in Adult ADHD Self-Report Scale (ASRS), eligibilityModule sex: ALL, minimumAge: 4 Years, maximumAge: 14 Years, stdAges: CHILD, contactsLocationsModule locations facility: Cell Therapy Center, status: RECRUITING, city: Amman, zip: 00962, country: Jordan, contacts name: Hanan Jafar, PhD, role: CONTACT, phone: 00962798871087, email: hanan.jafar@gmail.com, contacts name: Abdallah Awidi, MD, role: CONTACT, phone: 0096265355000, phoneExt: 23960, email: abdalla.awidi@gmail.com, geoPoint lat: 31.95522, lon: 35.94503, hasResults: False
protocolSection identificationModule nctId: NCT06293937, orgStudyIdInfo id: 24-0300b, briefTitle: Impact of Front-of-package Labels on Weight Bias Among Latines, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2024-04-30, completionDateStruct date: 2024-04-30, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: University of North Carolina, Chapel Hill, class: OTHER, collaborators name: Duke University, collaborators name: Stanford University, descriptionModule briefSummary: The goal of this experiment is to examine the effects on explicit weight bias of a selection task using 4 different types of front-of-package food labels to select healthy or unhealthy foods among a sample of Latine and low English proficiency adults. The main questions this experiment aims to answer are:* Does the use of different front-of-package label designs in a selection task lead to different effects on explicit weight bias among Latine and low English proficiency consumers?* Does the use of different front-of-package label designs in a selection task lead to different effects on attribution of personal responsibility for body weight among Latine and low English proficiency consumers?Participants will be randomly assigned to 1 of 4 types of front-of-package label designs. They will view 3 sets of products (frozen meals, frozen pizzas, and frozen desserts), shown in random order. For each product set, participants will view 3 products shown in random arrangement, each with participants' randomly assigned label shown on the front of package. After viewing all 3 product types, participants will answer questions about explicit weight bias and attribution of responsibility for body weight. Researchers will compare results across label designs., conditionsModule conditions: Weight Prejudice, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 4000, type: ESTIMATED, armsInterventionsModule interventions name: Numerical label, interventions name: Interpretive text-only label, interventions name: Interpretive magnifying glass icon label, interventions name: Separated interpretive magnifying glass icon label, outcomesModule primaryOutcomes measure: Explicit weight bias, mean score, secondaryOutcomes measure: Attribution of personal responsibility for body weight, mean score, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 55 Years, stdAges: ADULT, contactsLocationsModule locations facility: The University of North Carolina at Chapel Hill's Gillings School of Global Public Health, city: Chapel Hill, state: North Carolina, zip: 27599, country: United States, contacts name: Aline D'Angelo Campos, MPP, role: CONTACT, phone: 919-966-3215, email: adangelo-campos@unc.edu, geoPoint lat: 35.9132, lon: -79.05584, hasResults: False
protocolSection identificationModule nctId: NCT06293911, orgStudyIdInfo id: 2024-POSTBIOTICSDOWNSYNDROME, briefTitle: Clinical Comparison of a Postbiotic-gel With Placebo Gel for Gingival Inflammation in Patients With Down Syndrome, statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2024-03-15, primaryCompletionDateStruct date: 2025-07-17, completionDateStruct date: 2025-07-28, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: University of Pavia, class: OTHER, descriptionModule briefSummary: The aim of the study is to evaluate the efficacy of home treatment with a postbiotic-based gel for the management of periodontal inflammation in patients with Down syndrome.Patients will be enrolled at the S.C. Odontostomatologia dell'Azienda Ospedaliera "Ordine Mauriziano di Torino", Turin, Italy. After the collection of the periodontal clinical indexes (BoP%, PCR%, dental mobility, mMGI, compliance and satisfaction questionnaire), patients will undergo a professional mechanical debridement with ultrasonic instruments and glycine powders.Then, they will be randomly divided into two groups according to the home treatment:* in the Trial group Biorepair Plus Parodontgel Intensive (containing microRepair®, hyaluronic acid, Lactobacillus Ferment and Aloe Barbadensis Leaf Juice Powder) will be used once a day for all the duration of the study* in the Control group, a placebo gel without (active ingredients) will be used once a day for all the duration of the study.Indexes will be re-evaluated after 1 (T1), 3 (T2) and 6 months. The professional mechanical debridement will be performed again at T3 timepoint., conditionsModule conditions: Down Syndrome, conditions: Gingival Bleeding, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Biorepair Plus Parodontgel Intensive, interventions name: Placebo gel, outcomesModule primaryOutcomes measure: Change in Bleeding on Probing (BOP%), primaryOutcomes measure: Change in Plaque Control Record (PCR%), primaryOutcomes measure: Change in Dental mobility, primaryOutcomes measure: Change in Modified Gingival Index, primaryOutcomes measure: Change in compliance, primaryOutcomes measure: Change in product satisfaction, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: S.C. Odontostomatologia - Azienda Ospedaliera "Ordine Mauriziano di Torino", city: Turin, zip: 10128, country: Italy, geoPoint lat: 45.07049, lon: 7.68682, hasResults: False
protocolSection identificationModule nctId: NCT06293898, orgStudyIdInfo id: BL-M07D1-ST-101, briefTitle: Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-09, primaryCompletionDateStruct date: 2025-08-24, completionDateStruct date: 2027-08-24, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: SystImmune Inc., class: INDUSTRY, descriptionModule briefSummary: The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors., conditionsModule conditions: Endometrial Cancer, conditions: Cervical Cancer, conditions: Ovarian Cancer, conditions: Urothelial Carcinoma, conditions: Biliary Tract Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SEQUENTIAL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 280, type: ESTIMATED, armsInterventionsModule interventions name: BL-M07D1, outcomesModule primaryOutcomes measure: Summary of safety, primaryOutcomes measure: To determine the maximum tolerated dose (MTD) if reached or maximum administered dose (MAD) and two or more recommended doses for dose expansion (RDEs) of BL-M07D1, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: SystImmune Recruiting Site, status: RECRUITING, city: Houston, state: Texas, zip: 77030, country: United States, contacts name: SystImmune, role: CONTACT, geoPoint lat: 29.76328, lon: -95.36327, hasResults: False
protocolSection identificationModule nctId: NCT06293885, orgStudyIdInfo id: PLUG-II, briefTitle: Pleurodesis Using Hypertonic Glucose, acronym: PLUG-II, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-30, primaryCompletionDateStruct date: 2025-04-30, completionDateStruct date: 2025-04-30, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: Lawson Health Research Institute, class: OTHER, descriptionModule briefSummary: Air leaks from unhealed lung tissue following lung resection for benign or malignant lesions are one of the most common complications following thoracic surgery, occurring after 10% of major lung resections. The purpose of this study is to investigate the efficacy of intrapleural administration of Dextrose 50% to resolve air leaks after pulmonary resection., conditionsModule conditions: Air Leak From Lung, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Dextrose 50, interventions name: Standard of Care - No Dextrose 50, outcomesModule primaryOutcomes measure: Prolonged Air Leak, secondaryOutcomes measure: Duration of Chest Tubes, secondaryOutcomes measure: Home with Chest Tube, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: London Health Sciences Centre, city: London, state: Ontario, zip: N6A 5W9, country: Canada, geoPoint lat: 42.98339, lon: -81.23304, hasResults: False
protocolSection identificationModule nctId: NCT06293872, orgStudyIdInfo id: IZC miniscrew, briefTitle: Evaluation of Two Mini-Implant Lengths in the Infra-Zygomatic Crest Region, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-02-25, primaryCompletionDateStruct date: 2023-07-10, completionDateStruct date: 2023-12-28, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: University of Baghdad, class: OTHER, descriptionModule briefSummary: Evaluation of two different lengths of mini-implants in the infrazygomatic area regarding primary stability, pain perception, sinus penetration, secondary stability and failure rate., conditionsModule conditions: Orthodontic Appliance Complication, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 24, type: ACTUAL, armsInterventionsModule interventions name: 12*2 mm length miniscrew, outcomesModule primaryOutcomes measure: failure rate, secondaryOutcomes measure: primary stability, secondaryOutcomes measure: secondary stability, secondaryOutcomes measure: pain perception, eligibilityModule sex: ALL, minimumAge: 15 Years, maximumAge: 50 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: University of Baghdad College of Dentistry, city: Baghdad, zip: 10011, country: Iraq, geoPoint lat: 33.34058, lon: 44.40088, hasResults: False
protocolSection identificationModule nctId: NCT06293859, orgStudyIdInfo id: 5047292, briefTitle: Effect of 12-week Probiotic Consumption Immobilized on Oat Flakes on Blood and Urine Biomarkers and Human Microbiome, acronym: FOODBIOMES CT2, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-02-15, primaryCompletionDateStruct date: 2023-07-07, completionDateStruct date: 2023-07-30, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: University of the Aegean, class: OTHER, collaborators name: Democritus University of Thrace, descriptionModule briefSummary: The purpose of this clinical trial was to evaluate the effects Lactococcus cremoris spp. im-mobilized on oat flakes on human microbiome and blood and urine biomarkers of associated with human health., conditionsModule conditions: Healthy, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 54, type: ACTUAL, armsInterventionsModule interventions name: Probiotic oat flakes, interventions name: Conventional oat flakes, outcomesModule primaryOutcomes measure: Inflammatory biomarkers, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of the Aegean, city: Myrina, state: Limnos/Lesvos, zip: 81 400, country: Greece, geoPoint lat: 39.87483, lon: 25.06359, hasResults: False
protocolSection identificationModule nctId: NCT06293846, orgStudyIdInfo id: IRB-300012108, secondaryIdInfos id: IRB Designation, type: OTHER, domain: UAB, briefTitle: BeFit Toolbox Collaboration: Building Empowerment Through Fitness, acronym: BEFIT, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-15, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2026-12-31, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: University of Alabama at Birmingham, class: OTHER, descriptionModule briefSummary: This project will identify the causative behavioral factors in low-income African American women leading to sedentarism, a major source of morbidity in HABD communities. Working with our partner, WUCN, we will engage with women in HABD housing to develop and (later) deliver a physical activity education program (BeFit) customized for this population., conditionsModule conditions: Low-Income Population, conditions: Women's Health, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: HEALTH_SERVICES_RESEARCH, maskingInfo masking: NONE, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: What I Learned at Home, outcomesModule primaryOutcomes measure: Barriers to Physical Activity Self-Report, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of Alabama at Birmingham, status: RECRUITING, city: Birmingham, state: Alabama, zip: 35233, country: United States, contacts name: Kimberly McCall, PhD, role: CONTACT, phone: 205-934-3378, email: kmccall@uab.edu, contacts name: Keith Mcgregor, PhD, role: CONTACT, phone: 3523598084, phoneExt: Mcgregor, email: kmmcgreg@uab.edu, contacts name: Keith Mcgregor, role: SUB_INVESTIGATOR, geoPoint lat: 33.52066, lon: -86.80249, hasResults: False
protocolSection identificationModule nctId: NCT06293833, orgStudyIdInfo id: 003315, briefTitle: Implementation of Lung Cancer Screening in the First Line Zone of ZORA (Flanders), Using a Low Dose CT-scan, acronym: ZORALCS, statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2024-09-01, primaryCompletionDateStruct date: 2026-01-01, completionDateStruct date: 2026-01-01, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: University Hospital, Antwerp, class: OTHER, collaborators name: Universiteit Antwerpen, collaborators name: Belgian Cancer Registry, descriptionModule briefSummary: The goal of this clinical trial is to implement lung cancer screening in a targeted high-risk population of heavy (ex-)smokers in Flanders (Belgium). This implementation study will investigate the participation rate of eligible high risk (ex-)smokers in the First Line Zone South East Region of Antwerp (ZORA) in a LDCT screening program, combined with smoking cessation., conditionsModule conditions: Lung Cancer, Nonsmall Cell, conditions: Lung Cancer, conditions: Smoking Cessation, conditions: Lung Cancer, Small Cell, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: SCREENING, maskingInfo masking: NONE, enrollmentInfo count: 700, type: ESTIMATED, armsInterventionsModule interventions name: Low-dose CT scan, interventions name: Smoking Cessation, outcomesModule primaryOutcomes measure: Participation rate of eligible high-risk (ex-)smokers in ELZ-ZORA, secondaryOutcomes measure: Responders, secondaryOutcomes measure: Number of true and false positive nodules, secondaryOutcomes measure: Impact of smoking cessation intervention, secondaryOutcomes measure: Success of smoking cessation intervention, secondaryOutcomes measure: Evaluation of shared decision making tool, eligibilityModule sex: ALL, minimumAge: 55 Years, maximumAge: 74 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: UZA, city: Edegem, state: Antwerp, zip: 2650, country: Belgium, geoPoint lat: 51.15662, lon: 4.44504, hasResults: False
protocolSection identificationModule nctId: NCT06293820, orgStudyIdInfo id: TL-925-304, briefTitle: A Study Of TL-925 For The Treatment of AC, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2024-05, completionDateStruct date: 2024-05, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: Telios Pharma, Inc., class: INDUSTRY, descriptionModule briefSummary: In this prospective, Phase 2, randomized, double-masked, vehicle controlled study, approximately 70 eligible subjects will be randomized 1:1 to receive either TL-925 or placebo as topical ophthalmic eye drops administered bilaterally.The study comprises of a screening and treatment period using the conjunctival allergen challenge model to evaluate TL-925 for the treatment of allergic conjunctivitis., conditionsModule conditions: Allergic Conjunctivitis, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, maskingDescription: The sponsor, investigators, and study staff will be masked throughout the study. The study site will have the capacity to unmask in case of emergency.Following completion of the study, the randomization code will be unmasked once all data has been entered into the study database for every subject, and the database has been locked., whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 70, type: ESTIMATED, armsInterventionsModule interventions name: TL-925, interventions name: Placebo, outcomesModule primaryOutcomes measure: Ocular Itching, primaryOutcomes measure: Conjunctival Redness, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Andover Eye Associates, status: RECRUITING, city: Andover, state: Massachusetts, zip: 01810, country: United States, geoPoint lat: 42.65843, lon: -71.137, hasResults: False